Redcare Pharmacy Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Redcare Pharmacy is forecast to grow earnings and revenue by 54.3% and 17.5% per annum respectively. EPS is expected to grow by 119.5% per annum. Return on equity is forecast to be 8.1% in 3 years.

Anahtar bilgiler

54.3%

Kazanç büyüme oranı

119.5%

EPS büyüme oranı

Consumer Retailing kazanç büyümesi10.6%
Gelir büyüme oranı17.5%
Gelecekteki özkaynak getirisi8.1%
Analist kapsamı

Good

Son güncelleme28 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Is There Now An Opportunity In Redcare Pharmacy NV (ETR:RDC)?

Apr 21
Is There Now An Opportunity In Redcare Pharmacy NV (ETR:RDC)?

Are Investors Undervaluing Redcare Pharmacy NV (ETR:RDC) By 26%?

Apr 07
Are Investors Undervaluing Redcare Pharmacy NV (ETR:RDC) By 26%?

Investors Interested In Redcare Pharmacy NV's (ETR:RDC) Revenues

Mar 25
Investors Interested In Redcare Pharmacy NV's (ETR:RDC) Revenues

Redcare Pharmacy (ETR:RDC) Is Carrying A Fair Bit Of Debt

Feb 13
Redcare Pharmacy (ETR:RDC) Is Carrying A Fair Bit Of Debt

Why Investors Shouldn't Be Surprised By Redcare Pharmacy NV's (ETR:RDC) P/S

Dec 24
Why Investors Shouldn't Be Surprised By Redcare Pharmacy NV's (ETR:RDC) P/S

Is There An Opportunity With Redcare Pharmacy NV's (ETR:RDC) 48% Undervaluation?

Dec 06
Is There An Opportunity With Redcare Pharmacy NV's (ETR:RDC) 48% Undervaluation?

Is Redcare Pharmacy (ETR:RDC) Using Too Much Debt?

Sep 07
Is Redcare Pharmacy (ETR:RDC) Using Too Much Debt?

Why Redcare Pharmacy NV (ETR:RDC) Could Be Worth Watching

Aug 02
Why Redcare Pharmacy NV (ETR:RDC) Could Be Worth Watching

Why We're Not Concerned About Redcare Pharmacy NV's (ETR:RDC) Share Price

Jul 17
Why We're Not Concerned About Redcare Pharmacy NV's (ETR:RDC) Share Price

Broker Revenue Forecasts For Shop Apotheke Europe N.V. (ETR:SAE) Are Surging Higher

May 28
Broker Revenue Forecasts For Shop Apotheke Europe N.V. (ETR:SAE) Are Surging Higher

Here's Why Shop Apotheke Europe (ETR:SAE) Can Afford Some Debt

May 11
Here's Why Shop Apotheke Europe (ETR:SAE) Can Afford Some Debt

We Think Shop Apotheke Europe (ETR:SAE) Has A Fair Chunk Of Debt

Jan 10
We Think Shop Apotheke Europe (ETR:SAE) Has A Fair Chunk Of Debt

Is Shop Apotheke Europe (ETR:SAE) Using Too Much Debt?

Sep 25
Is Shop Apotheke Europe (ETR:SAE) Using Too Much Debt?

Is Shop Apotheke Europe (ETR:SAE) Weighed On By Its Debt Load?

Jun 08
Is Shop Apotheke Europe (ETR:SAE) Weighed On By Its Debt Load?

Is Shop Apotheke Europe (ETR:SAE) Using Too Much Debt?

Feb 28
Is Shop Apotheke Europe (ETR:SAE) Using Too Much Debt?

Here's Why Shop Apotheke Europe (ETR:SAE) Has A Meaningful Debt Burden

Aug 01
Here's Why Shop Apotheke Europe (ETR:SAE) Has A Meaningful Debt Burden

Shop Apotheke Europe N.V.'s (ETR:SAE) About To Shift From Loss To Profit

May 11
Shop Apotheke Europe N.V.'s (ETR:SAE) About To Shift From Loss To Profit

Shop Apotheke Europe (ETR:SAE) Has A Somewhat Strained Balance Sheet

Apr 14
Shop Apotheke Europe (ETR:SAE) Has A Somewhat Strained Balance Sheet

Insider Buying: The Shop Apotheke Europe N.V. (ETR:SAE) Chairman of the Managing Board & CEO Just Bought €96k Worth Of Shares

Mar 14
Insider Buying: The Shop Apotheke Europe N.V. (ETR:SAE) Chairman of the Managing Board & CEO Just Bought €96k Worth Of Shares

Kazanç ve Gelir Büyüme Tahminleri

XTRA:RDC - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (EUR Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/20263,537685412712
12/31/20252,93010118012
12/31/20242,386-34-134812
6/30/20242,128-9-833N/A
3/31/20241,987-10038N/A
12/31/20231,799-122361N/A
9/30/20231,595-16-240N/A
6/30/20231,404-45-1333N/A
3/31/20231,272-65-59-9N/A
12/31/20221,204-78-83-29N/A
9/30/20221,165-110-68-16N/A
6/30/20221,118-105-481N/A
3/31/20221,081-91-406N/A
12/31/20211,060-74-3212N/A
9/30/20211,037-39-1435N/A
6/30/20211,038-29-2827N/A
3/31/20211,020-18-1735N/A
12/31/2020968-17-3618N/A
9/30/2020895-15-56-19N/A
6/30/2020827-20-43-19N/A
3/31/2020758-27-38-16N/A
12/31/2019701-36-45-31N/A
9/30/2019660-41-25-11N/A
6/30/2019621-40-22-10N/A
3/31/2019584-40-39-26N/A
12/31/2018540-34-26-15N/A
9/30/2018481-31-40-31N/A
6/30/2018415-28-38-24N/A
3/31/2018351-24N/A-17N/A
12/31/2017284-21N/A-23N/A
9/30/2017244-22N/A-11N/A
6/30/2017222-20N/A-16N/A
3/31/2017200-20N/A-14N/A
12/31/2016177-18N/A-17N/A
9/30/2016159-13N/A-5N/A
6/30/2016147-13N/A-5N/A
3/31/2016136-12N/A-7N/A
12/31/2015126-11N/A-9N/A
12/31/201485-5N/A-4N/A
12/31/201355-3N/A-4N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: RDC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.8%).

Kazançlar ve Piyasa: RDC is forecast to become profitable over the next 3 years, which is considered above average market growth.

Yüksek Büyüme Kazançları: RDC is expected to become profitable in the next 3 years.

Gelir ve Pazar: RDC's revenue (17.5% per year) is forecast to grow faster than the German market (5.5% per year).

Yüksek Büyüme Geliri: RDC's revenue (17.5% per year) is forecast to grow slower than 20% per year.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: RDC's Return on Equity is forecast to be low in 3 years time (8.1%).


Büyüyen şirketleri keşfedin